Ranibizumab PDS Implant for Diabetic Retinopathy
(PAVILION Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator Arm
Who Is on the Research Team?
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Are You a Good Fit for This Trial?
Adults over 18 with diabetic retinopathy but no macular edema can join. They must have a certain level of retina damage and controlled diabetes (HbA1c ≤12%). Excluded are those with prior eye treatments like corticosteroids or anti-VEGF, recent heart issues, uncontrolled glaucoma, infections, or conditions needing future eye surgery.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the PDS implant with ranibizumab and undergo refill-exchange procedures every 36 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Intravitreal Ranibizumab 0.5 mg Injection
- PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University